Merck-backed asset Imago BioSciences was acquired by Merck for $1.35B in 2022 and is in merger with Merck’s subsidiary, signaling strong corporate backing and potential access to Merck’s global development and commercialization capabilities for IMG-7289 and related LSD1 programs.

LSD1 focus The company’s flagship asset IMG-7289 is a selective LSD1 inhibitor targeting myeloproliferative neoplasms, creating sales opportunities with pharma and CRO partners for clinical development support, companion diagnostics, or expansion into related hematologic indications.

Lean operations With a small workforce and pre-revenue status, Imago relies on external partners for many functions, presenting clear opportunities for contract research, clinical operations, manufacturing, and other outsourced services positioned to support late-stage development.

Leadership signals Strategic leadership hires in 2021-2022 and board additions indicate a push to advance development and business development, suggesting receptiveness to licensing, collaboration deals, or partnerships with larger pharma or biotech entities.

Market interest The presence of competitive players in the LSD1 space and Merck’s involvement imply growing market interest in LSD1 inhibitors; this creates a window to engage potential partners for licensing, co-development, or supply agreements to accelerate IMG-7289’s clinical and potential commercial trajectories.